Kura Oncology Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(In thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Par Value | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2020 | 66,194 | $7 | $913,354 | $46 | $(302,502) | $610,905 |
| Share-based compensation expense | — | — | 23,579 | — | — | 23,579 |
| Issuance of common stock under equity plans | 378 | — | 4,426 | — | — | 4,426 |
| Other comprehensive loss | — | — | — | (1,835) | — | (1,835) |
| Net loss | — | — | — | — | (130,466) | (130,466) |
| Balance as of December 31, 2021 | 66,572 | 7 | 941,359 | (1,789) | (432,968) | 506,609 |
| Issuance of common stock, net of offering costs | 1,370 | — | 24,721 | — | — | 24,721 |
| Share-based compensation expense | — | — | 26,318 | — | — | 26,318 |
| Issuance of common stock under equity plans | 372 | — | 4,419 | — | — | 4,419 |
| Issuance of warrants in connection with debt facility | — | — | 294 | — | — | 294 |
| Other comprehensive loss | — | — | — | (6,243) | — | (6,243) |
| Net loss | — | — | — | — | (135,840) | (135,840) |
| Balance as of December 31, 2022 | 68,314 | 7 | 997,111 | (8,032) | (568,808) | 420,278 |
| Issuance of common stock, net of offering costs | 5,661 | — | 60,919 | — | — | 60,919 |
| Issuance of pre-funded warrants to purchase common stock, net of offering costs | — | — | 32,658 | — | — | 32,658 |
| Share-based compensation expense | — | — | 28,082 | — | — | 28,082 |
| Issuance of common stock under equity plans | 375 | — | 1,206 | — | — | 1,206 |
| Other comprehensive income | — | — | — | 6,761 | — | 6,761 |
| Net loss | — | — | — | — | (152,631) | (152,631) |
| Balance as of December 31, 2023 | 74,350 | $7 | $1,119,976 | $(1,271) | $(721,439) | $397,273 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.